Archives
Diphenyleneiodonium Chloride: GPR3 Agonist and Redox Enzy...
Diphenyleneiodonium Chloride: GPR3 Agonist and Redox Enzyme Inhibitor
Executive Summary: Diphenyleneiodonium chloride (DPI) irreversibly inhibits NADH oxidases (NOX) and nitric oxide synthases (NOS), with an EC50 of 0.1 μM for NOX inhibition and a Ki of 2.8 μM for cytochrome P450 reductase inhibition [APExBIO B6326]. DPI is a validated G protein-coupled receptor 3 (GPR3) agonist, inducing cAMP accumulation in mammalian cells independently of NOX inhibition [Protein-Kinase-C.com]. DPI is insoluble in water and ethanol but dissolves in DMSO at ≥6.99 mg/mL with sonication [APExBIO B6326]. It is widely used in oxidative stress, cancer, and neurodegenerative disease model systems (Hao et al., 2025). The compound is supplied by APExBIO and is intended for research use only.
Biological Rationale
DPI targets fundamental redox and signaling enzymes critical for cell function. NADH oxidase (NOX) enzymes generate reactive oxygen species (ROS) involved in cellular signaling, host defense, and oxidative stress-related pathologies (Hao et al., 2025). Nitric oxide synthases (NOS) produce nitric oxide (NO), a key mediator in immune response, vasodilation, and inflammation. Excessive ROS and NO contribute to cell damage, ferroptosis, and disease progression in cancer and neurodegenerative models. G protein-coupled receptor 3 (GPR3) is a Gs-linked receptor that regulates intracellular cAMP levels, impacting neuronal signaling, energy metabolism, and inflammatory cascades [n6-methyl.com]. DPI enables precise manipulation of these pathways, supporting research on redox homeostasis, ferroptosis, and cAMP-mediated processes.
Mechanism of Action of Diphenyleneiodonium chloride
- NOX and NOS Inhibition: DPI inhibits flavoprotein-containing enzymes by forming covalent adducts at the flavin site, blocking electron transfer and ROS production. This inhibition is irreversible under physiological conditions [APExBIO B6326].
- Cytochrome P450 Reductase: DPI blocks cytochrome P450 reductase with a Ki of 2.8 μM, affecting xenobiotic metabolism and redox balance [APExBIO B6326].
- GPR3 Agonism: DPI directly activates GPR3 receptors, promoting cAMP accumulation, receptor desensitization, calcium influx, and β-arrestin2 recruitment in transfected cells [Protein-Kinase-C.com].
- cAMP Signaling Modulation: DPI elevates cAMP independently of redox inhibition, uniquely separating GPR3-mediated effects from NOX/NOS pathways [n6-methyl.com].
Evidence & Benchmarks
- DPI inhibits NOX activity with an EC50 of 0.1 μM in cell-free and cell-based systems (APExBIO B6326).
- Acts as an irreversible inhibitor of nitric oxide synthase, blocking NO production in vitro and in vivo (Hao et al., 2025).
- Induces cAMP accumulation and β-arrestin2 recruitment in GPR3-expressing HEK293 and HeLa cells (Protein-Kinase-C.com).
- Inhibits cytochrome P450 reductase with a Ki of 2.8 μM, confirmed by enzyme kinetics (APExBIO B6326).
- Applied in studies modeling ferroptosis, oxidative stress, and cAMP-dependent cellular responses (SuzetrigineCompound.com).
This article extends the detailed workflows in "Diphenyleneiodonium Chloride: Precision Tool for Redox En..." by providing an updated review of GPR3 agonism, as well as clarifying DPI's dual mechanism compared to "Diphenyleneiodonium Chloride: GPR3 Agonist and Redox Enzy...".
Applications, Limits & Misconceptions
- DPI is widely used in oxidative stress research, including cancer, neurodegenerative, and cardiovascular disease models (Hao et al., 2025).
- It serves as a tool to probe NOX and NOS-dependent signal transduction, ferroptosis, and inflammation.
- DPI’s GPR3 agonism enables studies of cAMP signaling pathways and β-arrestin recruitment [n6-methyl.com].
- SKU B6326 is intended for research use only. It is not suitable for diagnostic or therapeutic application (APExBIO B6326).
Common Pitfalls or Misconceptions
- DPI is not selective for a single enzyme class. It inhibits multiple flavoprotein enzymes, which may confound pathway-specific studies.
- Not water- or ethanol-soluble. DPI should be dissolved in DMSO at ≥6.99 mg/mL with ultrasonic assistance for reproducible results.
- Irreversible inhibition can mask transient signaling effects. Use with caution in kinetic or time-resolved assays.
- Not suitable for in vivo diagnostic or clinical use. DPI is strictly for laboratory research (APExBIO B6326).
- Storage: DPI must be desiccated at -20°C; solutions are not stable long-term.
Workflow Integration & Parameters
- DPI is supplied as a crystalline solid (molecular weight: 314.55; formula: C12H8ClI) and shipped on blue ice [APExBIO B6326].
- For cell-based assays, dissolve DPI in DMSO; avoid water or ethanol due to insolubility.
- Recommended assay concentrations: 0.01–10 μM for NOX/NOS inhibition; titrate for GPR3-dependent cAMP signaling studies.
- Store solid DPI at -20°C in a desiccator; use freshly prepared solutions for maximal activity.
- Integrates with cell viability, oxidative stress, calcium influx, and β-arrestin2 recruitment assays (Flunarizinemed.com).
This article clarifies DPI’s integration into GPCR and redox workflows compared to "Diphenyleneiodonium Chloride (SKU B6326): Scenario-Based ..." by specifying storage and solubility limitations.
Conclusion & Outlook
Diphenyleneiodonium chloride (DPI, B6326) from APExBIO is a uniquely dual-function research tool: a potent irreversible NOX/NOS inhibitor and a GPR3 agonist for cAMP signaling studies. Its ability to dissect redox and GPCR pathways in parallel supports advanced research in oxidative stress, ferroptosis, and cell signaling modulation. Future studies may further delineate DPI’s specificity and enable the next generation of pathway-selective probes. For more information and ordering, see the product page.